A retrospective review of ampicillin-sulbactam and amoxicillin + clavulanate vs cefazolin/cephalexin and erythromycin in the setting of preterm premature rupture of membranes: maternal and neonatal outcomes

Ehsanipoor, Robert M.; Chung, Judith H.; Clock, Charlotte; McNulty, Jennifer

doi:10.1016/j.ajog.2007.12.022

Cited by 35 publications

(23 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Antimicrobial agents are prescribed to eradicate existing subclinical intra-amniotic infection, or to prevent secondary ascending infection into the amniotic cavity [1,35,36,78–89]. Randomized clinical trials [90–104] and systematic reviews [2,105–108] indicate that antibiotic administration has short-term benefits for both pregnant women and their neonates, including prolonged pregnancy [2,91–97,99–102,105,109], reduction of neonatal respiratory distress syndrome [2,92,100,102], infection-related morbidity [2,90–92,94,98–100,102,105,106,109], and necrotizing enterocolitis [2,100,102]. Whether the short-term benefits translate into long-term health outcomes is not clear.…”

Section: Introductionmentioning

confidence: 99%

“…Several antibiotic regimens have been used in patients with preterm PROM, including ampicillin [90,93,97,99,100,108,111–113], amoxicillin-clavulanate [93,102,108], penicillin [94], erythromycin [92,95,97,100,102,108,114], mezlocillin [97], pipericillin [96], cefexin [115], cefizox [116], gentamicin [93], clindamycin [93], azithromycin [113,117] and combinations of different agents [89,109]. The currently recommended practice varies in the United States and Europe.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A new antibiotic regimen treats and prevents intra-amniotic inflammation/infection in patients with preterm PROM

Lee

Romero

Kim

et al. 2015

The Journal of Maternal-Fetal & Neonatal Medicine

View full text Add to dashboard Cite

Objective To determine if a new antibiotic regimen could reduce the frequency of intra-amniotic inflammation/infection in patients with preterm PROM. Study design This retrospective cohort study was conducted to evaluate the effect of antibiotics on the frequency of intra-amniotic inflammation/infection based on the results of follow-up transabdominal amniocenteses from 89 patients diagnosed with preterm PROM who underwent serial amniocenteses. From 1993–2003, ampicillin and/or cephalosporins or a combination was used (“regimen 1”). A new regimen (ceftriaxone, clarithromycin, and metronidazole) was used from 2003–2012 (“regimen 2”). Amniotic fluid was cultured and matrix metalloproteinase-8 (MMP-8) concentrations were measured. Results 1) The rates of intra-amniotic inflammation and intra-amniotic inflammation/infection in patients who received regimen 2 decreased during treatment from 68.8% to 52.1% and from 75% to 54.2%, respectively. In contrast, in patients who received regimen 1, the frequency of intra-amniotic inflammation and infection/inflammation increased during treatment (31.7% to 55% and 34.1% to 58.5%, respectively); and 2) intra-amniotic inflammation/infection was eradicated in 33.3% of patients who received regimen 2, but in none who received regimen 1. Conclusion The administration of ceftriaxone, clarithromycin, and metronidazole was associated with a more successful eradication of intra-amniotic inflammation/infection and prevented secondary intra-amniotic inflammation/infection more frequently than an antibiotic regimen which included ampicillin and/or cephalosporins in patients with preterm PROM.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A new antibiotic regimen treats and prevents intra-amniotic inflammation/infection in patients with preterm PROM

Lee

Romero

Kim

et al. 2015

The Journal of Maternal-Fetal & Neonatal Medicine

View full text Add to dashboard Cite

show abstract

“…21,22 Other investigators have not found such an association, or have found an association between antenatal antibiotic administration and reduced incidence of NEC. 19,23,24 We performed a retrospective, case-controlled study of newborns with NEC born at our institution between 1988 and 2006 to test the hypothesis that antenatal antibiotic exposure is associated with a greater risk of NEC.…”

Section: Introductionmentioning

confidence: 99%

Antenatal antibiotic exposure in preterm infants with necrotizing enterocolitis

Ferrara

DeLuca

et al. 2011

J Perinatol

View full text Add to dashboard Cite

Objective: To determine whether an association exists between antenatal antibiotic exposure and incidence of necrotizing enterocolitis (NEC) in low birth weight infants.Study Design: A retrospective case-control study was performed on all infants with a diagnosis of NEC born at our institition between 1988 and 2006. Medical histories of all infants with a diagnosis of NEC XBell's stage IIA and matched controls without NEC were reviewed. Maternal and neonatal characteristics were compared using the Mantel-Haenszel chi-square procedure, and logistic regression models were constructed to account for confounding.Result: Clinical data for 97 matched pairs were analyzed. The adjusted odds ratio (OR) for antenatal exposure to ampicillin was significantly greater for infants who developed NEC (OR 2.3, 95% confidence interval 1.1, 4.8, P ¼ 0.003) than for control infants. Conclusion:Infants who developed NEC were more likely to have a history of in utero exposure to ampicillin in the immediate antepartum period than infants who did not develop NEC.

show abstract

“…A few studies have suggested a correlation between maternal exposure of amoxicillin/clavulanate and the development of NEC,[585960] while other studies have not found such an association. [6162] The data for antenatal steroid use is also controversial, as several studies noted no significant increase in the incidence of NEC associated with prenatal use of steroids,[636465] while a much larger study did appreciate a correlation. [41]…”

Section: Maternal Risk Factorsmentioning

confidence: 99%

Predicting disease severity of necrotizing enterocolitis: How to identify infants for future novel therapies

2014

View full text Add to dashboard Cite

Necrotizing enterocolitis (NEC) remains a very devastating problem within the very low birth weight neonatal population. Several experimental therapies are being tested in animal models and soon may be ready for human trials. Despite this progress, we currently have no way to identify infants who would be optimal targets for therapy. Specifically, we are unable to predict which infants will progress to the more severe Bell's stage of disease that may necessitate surgery. Ideally, an algorithm could be constructed that would encompass multiple neonatal and maternal risk factors as well as potential biologic markers of disease so that these infants could be identified in a more timely fashion. This review summarizes the known risk factors and biomarkers of disease in hopes of stimulating clinical research to identify such an “early warning” NEC algorithm.

show abstract

A retrospective review of ampicillin-sulbactam and amoxicillin + clavulanate vs cefazolin/cephalexin and erythromycin in the setting of preterm premature rupture of membranes: maternal and neonatal outcomes

Cited by 35 publications

References 6 publications

A new antibiotic regimen treats and prevents intra-amniotic inflammation/infection in patients with preterm PROM

A new antibiotic regimen treats and prevents intra-amniotic inflammation/infection in patients with preterm PROM

Antenatal antibiotic exposure in preterm infants with necrotizing enterocolitis

Predicting disease severity of necrotizing enterocolitis: How to identify infants for future novel therapies

Contact Info

Product

Resources

About